Myopia control in the real world: treatments, target, timing, and terminus

Información del proyecto

CONTROL-MYOPIA

Identificador del acuerdo de subvención: 101098324

DOI

10.3030/101098324

Fecha de la firma de la CE 20 Septiembre 2023

Fecha de inicio 1 Octubre 2023

Fecha de finalización 30 Septiembre 2028

Financiado con arreglo a

• European Research Council (ERC)

Coste total

€ 2 500 000,00

Aportación de la UE

€ 2 500 000,00

Coordinado por

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands

Periodic Reporting for period 1 - CONTROL-MYOPIA (Myopia control in the real world: treatments, target, timing, and terminus)

Período documentado: 2023-10-01 hasta 2026-03-31

Resumen del contexto y de los objetivos generales del proyecto

Myopia is rising rapidly worldwide, driven by changing lifestyles, intensive education, and reduced outdoor exposure among children. By 2050, half of the global population is expected to be myopic, leading to a substantial increase in vision-threatening complications such as retinal detachment and myopic maculopathy. Although several preventive and therapeutic options are emerging, their effectiveness varies, long-term evidence is limited, and many eye-care professionals lack the tools needed to select the most appropriate intervention for each patient. This gap hinders timely and effective myopia management during the critical years of ocular development.

CONTROL-MYOPIA aims to transform patient care by developing an agile, AI-based clinical decision support system built on a strong scientific foundation of multidisciplinary data. The project will create population-based reference centiles for eye growth and myopia progression in Europe; collect high-quality, long-term real-world data on treatment timing, effectiveness, side effects, and acceptability; and identify patient characteristics associated with poor response or adherence. Advanced machine-learning techniques will be used to predict long-term myopia outcomes from a broad set of potential predictors. These components will be integrated into a user-centred, interactive platform that provides accurate prognoses and recommends the right preventive or therapeutic strategy for each child at the right time.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

CONTROL MYOPIA has developed region-specific reference centile charts for eye growth. Using advanced modelling aligned with World Health Organization growth chart methodology, we generated robust age- and sex-specific axial length centile charts for populations in Asia, Australia, and Europe, thereby providing a harmonised benchmark for interpreting axial length measurements across diverse populations. These growth curves are expected to be adopted for clinical use in myopia management. In addition, our publication by Kneepkens et al. in BMJ Public Health, “Trends in myopia prevalence and projected visual impairment in Western Europe: a pooled analysis of Dutch population-based cohorts (1900–2000)”, describes historical trends in myopia prevalence over the past century and projects future prevalence up to 2075, underscoring its relevance for policymakers and healthcare planning. In addition, we have taken the first steps toward predictive modelling by estimating adult axial length and final refractive error outcomes based on a comprehensive set of myopia predictors, including axial length, the axial length–to–corneal radius ratio (AL/CR), choroidal thickness (ChT), and lifestyle components.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Our findings on myopia prevalence, progression, and risk profiles also formed the basis for the development of a national guideline on childhood myopia, currently being revised by the Dutch Ophthalmology Society and expected to be published later this year; once implemented, it will directly inform clinical decision-making and standardise evidence-based lifestyle advice for children in routine care. In addition, as board members of Zicht op Buiten, my team and I organised and participated in numerous public outreach events to raise awareness of the protective effects of outdoor exposure and reduced tablet use on myopia, including the development of an instructional video accessible to children, parents, and schools nationwide. Finally, my team developed an evidence-based teaching curriculum derived from our scientific findings and delivered it across multiple clinical settings and industry contexts to update eye care professionals and the pharmaceutical industry on contemporary myopia management.